Journal Information
Vol. 38. Issue 8.
Pages 386-391 (August 2002)
Share
Share
Download PDF
More article options
Vol. 38. Issue 8.
Pages 386-391 (August 2002)
Full text access
Nuevas dianas y estrategias terapéuticas en el cáncer de pulmón
Visits
...
J. Sánchez De Cos Escuín
Unidad de Neumología. Hospital San Pedro de Alcántara. Cáceres
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
A.T. Turrisi, K. Kim, R. Blum, et al.
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
N Engl J Med, 340 (1999), pp. 265-271
[2.]
J.A. Bonner, J.A. Sloan, T.h.G. Shanahan, et al.
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.
J Clin Oncol, 17 (1999), pp. 2681-2691
[3.]
K. Furuse, M. Fukuoka, M. Kawahara, et al.
Phase II study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non small cell lung cancer.
J Clin Oncol, 17 (1999), pp. 2692-2699
[4.]
B. Jeremic, Y. Shibamato, S. Acimovic L Milisavljevic.
Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non small cell lung cancer: a randomized study.
J Clin Oncol, 14 (1996), pp. 1065-1070
[5.]
E.K. Rowinsky.
The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agent.
Drugs, 60 (2000), pp. 1-14
[6.]
Angiogenesis and metastasis growth (written in consultation with Judah Folkman) [editorial].
Advances in Oncology, 12 (1996), pp. 2-7
[7.]
A. Yuan, C.H.-.J. Yu, S.-.H. Kuo, et al.
Vascular endotelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival and postoperative relapse in non-small cell lung cancer.
J Clin Oncol, 19 (2001), pp. 441-443
[8.]
E.L. Lund, C.H. Thorsen, M.W.B. Pedersen, N. Junker, P.E.G. Kristjansen.
Relationship between vessel density and expression of vascular endotelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro.
Clin Cancer Res, 6 (2000), pp. 4287-4291
[9.]
C. López Otín.
Metaloproteinasas y progresión tumoral. Encuentros en Oncología (Segovia, 25-26 de marzo de 1999), pp. 15-16
[10.]
B. Passlick, W. Sienel, R. Seen-Hibler, et al.
Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
Clin Cancer Res, 6 (2000), pp. 3944-3948
[11.]
M. Birkhofer.
An overview of key compounds from the BMS oncology pipeline: matrix metalloproteinase inhibitor BMS-275291 and epothilone analog BMS-187550.
Encuentros en Oncología (Segovia, 5-6 de abril de 2001), pp. 33-35
[12.]
E. Díaz Rubio.
Oncofarmacogenómica.
Nuevos conceptos en los ensayos clínicos. Encuentros en Oncología, (2001),
[13.]
P. Bunn.
Translation of the biology of lung cancer to targeted therapies.
Educational Book. ASCO 2001. 31st Annual Meeting, (2001),
[14.]
H. Cortés Funes.
Antiangiogenesis agents. Encuentros en Oncología (Segovia, 5-6 de abril de 2001), pp. 29-32
[15.]
K.F. De Vore, L. Fehrenbacher, R.S. Herbst, et al.
A randomized phase II trial comparing Rhumab VEGF plus carboplatin and paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am.
Soc Clin Oncol, 19 (2000), pp. 485
[16.]
F.A. Shepherd, G. Giaccone, C. Debruyne, et al.
Randomized double- blind placebo controlled trial of marimastat in patients with small cell lung cancer following response to first line chemotherapy: an NCI-CTG and EORTC study.
Proc Am Soc Clin Oncol, 20 (2001), pp. 4
[17.]
M. Smylie, R. Mercier, D. Aboulafia, et al.
Phase III study of the matrix metalloproteinase (MMP) inhibitor Prinomastat in patients having advanced non-small cell lung cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 307
[18.]
M.G. Kris, S.A. Laurie, V.A. Miller.
Integrating new agents and approaches into chemotherapy regimens for non-small cell lung cancers.
Educational Book. ASCO 2000. 30st Annual Meeting, (2000),
[19.]
J. Mendelsohn.
Epidermal growth factor receptor blockade as anticancer therapy.
Educational Book. ASCO 2001. 31st Annual Meeting, (2001),
[20.]
E. Raymond, S. Faivre, J.P. Armand.
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.
Drugs, 60 (2000), pp. 15-23
[21.]
J. Baselga.
New therapeutic agents targeting the epidermal growth factor receptor.
J Clin Oncol, 18 (2000), pp. S54-S59
[22.]
F. Ciardello.
Epidermal growth factor receptor Tyrosine Kinase inhibitors as anticancer agents.
Drugs, 60 (2000), pp. 25-32
[23.]
J. Baselga, S.D. Averbuch.
ZD1839 (“Iressa”) as an anticancer agent.
Drugs, 60 (2000), pp. 33-40
[24.]
K. Nakagawa, N. Yamamoto, S. Kudoh, et al.
A phase I intermittent dose-escalation trial of ZD1839 in Japanese Patients with solid malignant tumours.
Proc Am Soc Clin Oncol, 19 (2000), pp. 183
[25.]
J. Baselga, R. Herbst, P. LoRusso, et al.
Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-TKI) in patients with five selected tumor types: Evidence of activity and good tolerability. Proc Am.
Soc Clin Oncol, 19 (2000), pp. 177
[26.]
D. Ferry, L. Hammond, M. Ranson, et al.
Intermittent oral ZD1389, a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a phase I study.
Proc Am Soc Clin Oncol, 19 (2000), pp. 3
[27.]
R. Pérez Soler, A. Chachoua, M. Huberman, et al.
A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, following platinum-base chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 310
[28.]
L.M. Krug, V.A. Miller, J. Crapanzano, et al.
Randomized phase II trial of Trastuzumab plus either Docetaxel or Paclitaxel in previously untreated advanced non-small cell lung cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 333
[29.]
Targeting the BCR-ABL Tyrosine Kinase in chronic myeloid leukemia [editorial].
N Engl J Med, 344 (2001), pp. 1084-1086
[30.]
B.J. Druker, M. Talpaz, D.R. Resta, et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med, 344 (2001), pp. 1031-1037
[31.]
B.J. Druker, C.L. Sawyers, H. Kantarjian, et al.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
N Engl J Med, 344 (2001), pp. 1038-1042
[32.]
H. Joensuu, P.J. Roberts, M. Sarlomo-rikala, et al.
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
N Engl J Med, 344 (2001), pp. 1052-1056
[33.]
G.W. Krystal, S. Honsawek, J. Litz, E. Buchdunger.
The Selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Clin Cancer Res, 6 (2000), pp. 3319-3326
[34.]
L.H. Camacho, S.L. Soignet, S. Pezzulli, et al.
Dose escalation of oral Farnesyl transferase inhibitor (FTI) BMS-214682 in patients with solid tumors. Proc Am.
Soc Clin Oncol, 20 (2001), pp. 79
[35.]
K.B. Kim, D.M. Shin, C.C. Summey, et al.
Phase I study of Farnesyl transferase inhibitor, BMS-214662 in solid tumors.
Proc Am Soc Clin Oncol, 20 (2001), pp. 79
[36.]
M. Voi, J. Tabernero, M.R. Cooper, et al.
A phase I study of the Farnesyl transferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients with advanced solid tumors: clinical findings.
Proc Am Soc Clin Oncol, 20 (2001), pp. 79
[37.]
H.J. Mackay, R. Hoekstra, F. Eskens, et al.
A phase I dose escalating study of BMS-214662 with cisplatin in patients with advanced solid tumors.
Proc Am Soc Clin Oncol, 20 (2001), pp. 80
[38.]
K. Nakagawa, N. Yamamoto, K. Nishio, et al.
A phase I pharmacokinetic and pharmacodynamic study of the Farnesyl transferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies.
Proc Am Soc Clin Oncol, 20 (2001), pp. 80
[39.]
M.J. Piccart-Gebhart, F. Branle, D. De Valerola, et al.
A phase I. clinical and pharmacokinetic trial of the Farnesyl transferase inhibitor (FTI) R115777 + Docetaxel: a promising combination in patients with solid tumors.
Proc Am Soc Clin Oncol, 20 (2001), pp. 80
[40.]
L. Liebes, H. Hochster, J. Speyer, et al.
Enhanced myelosuppression of Topotecan when combined with the Farnesyl transferase inhibitor, R115777: a phase I & pharmacodynamic study.
Proc Am Soc Clin Oncol, 20 (2001), pp. 81
[41.]
A.A. Adjer, C. Erlichman, R.S. Marks, et al.
A phase I trial of the Farnesyl transferase inhibitor, R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 81
[42.]
G. Fisher, R. Advani, M. Moore, et al.
Phase I/II trial of ISIS 3521, an antisense inhibitir of PKC-alpha, with Carboplatin and Paclitaxel in non-small cell lung cancer.
Proc Am Soc Clin Oncol, 20 (2001), pp. 309
Copyright © 2002. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología

Subscribe to our newsletter

Article options
Tools

Are you a health professional able to prescribe or dispense drugs?